Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.

about

Blocking signaling at the level of GLI regulates downstream gene expression and inhibits proliferation of canine osteosarcoma cells Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.

P2860

Q35165531-239DED78-7456-4F6B-9456-692DA30E4FF1 Q38113988-36152B9D-BC74-470E-AAAE-19D0CF80D37D

P2860

Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.

Item

http://www.wikidata.org/entity/Q36728942

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Evaluation of arsenic trioxide ...... with a focus on Ewing sarcoma.

@ast

Evaluation of arsenic trioxide ...... with a focus on Ewing sarcoma.

@en

type

Item

label

Evaluation of arsenic trioxide ...... with a focus on Ewing sarcoma.

@ast

Evaluation of arsenic trioxide ...... with a focus on Ewing sarcoma.

@en

prefLabel

Evaluation of arsenic trioxide ...... with a focus on Ewing sarcoma.

@ast

Evaluation of arsenic trioxide ...... with a focus on Ewing sarcoma.

@en

P1476

Evaluation of arsenic trioxide ...... with a focus on Ewing sarcoma

@en

P2093

Catherine A Billups

http://www.w3.org/2001/XMLSchema#string

Denise Alexander

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Toretsky

http://www.w3.org/2001/XMLSchema#string

Malcolm A Smith

http://www.w3.org/2001/XMLSchema#string

Peter J Houghton

http://www.w3.org/2001/XMLSchema#string

Raushan T Kurmasheva

http://www.w3.org/2001/XMLSchema#string

P2860

From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia

Arsenic trioxide inhibits human cancer cell growth and tumor development in mice by blocking Hedgehog/GLI pathway

Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector

Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemogenic process induced by the PML-RARalpha and PLZF-RARalpha oncoproteins

Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients

Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro.

Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia

Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.

National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testing

Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma.

P304

753-755

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.23391

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

C P Reynolds

M H Kang

P577

2012-02-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22315235

http://www.w3.org/2001/XMLSchema#string

P932

3612422

http://www.w3.org/2001/XMLSchema#string

Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.

about

P2860

P2860

Evaluation of arsenic trioxide by the pediatric preclinical testing program with a focus on Ewing sarcoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932